A first-of-its-kind drug targeting a fused gene found in many types of cancer was effective in 93 percent of pediatric patients tested, researchers at UT Southwestern’s Simmons Cancer Center announced. The research was published in March 2018 in The Lancet Oncology.
At age 10, Eden was diagnosed with a cancer type no doctor had ever seen. They crafted a treatment plan that made her cancer-free, but two years later she relapsed. Now 13, Eden is enrolled in an ALSF-funded clinical trial to try and cure her disease.